Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biotechnology company, Crucell has signed a non-exclusive Star research license agreement with Korean-based Isu Abxis that covers both a research evaluation of Star technology for the production of recombinant proteins and an option for a commercial license.
Subscribe to our email newsletter
Star technology is a production technology that is useful for the production of recombinant human antibodies and proteins. It is said to be effective for production of antibodies and proteins on mammalian cell lines such as Crucell’s PER.C6 human cell technology and the widely used Chinese hamster ovary (CHO) cell line. The technology also has the potential to increase production yields, thereby reducing production costs.